Onco Actu du 10 juin 2016

	1.1 Biologie - Gènes
Acute myeloid leukaemia is 11 different diseases [Cancer Research UK] Experts cautioned that there was more to discover before the findings could influence patient care.
	3.1.1 Tabac - e-cigs
Electronic Cigarette Use Among Working Adults — United States, 2014 [MMWR] In 2014, an estimated 3.8% of U.S. working adults were current e-cigarette users.
	3.5 Prévention - UV
12 sun safety myths debunked [Cancer Research UK] So with the sun out, we thought we’d clear up 12 common myths around sun safety to help you keep your skin healthy and reduce your risk of serious damage.
	4.9 Dép., diag. & prono. - Sein
Intrinsic molecular subtyping enables fine-tuned prognosis and prediction of tumor behavior in patients with advanced breast cancer [Vall d'Hebron Institute Oncology] Findings show that the genomic classification of tumors -- the molecular subtyping of primary tumors, can predict the evolution of patients from the onset of metastasis and that this cancer intrinsic classification can better guide treatment decisions in the first-line metastatic setting.
	5.12 Immunothérapies
A Scientist's Dream Fulfilled: Harnessing The Immune System To Fight Cancer [NPR] Allison's long search for this new kind of treatment — one that's since become a lifesaver for some cancer patients — began around a decade before Belvin got sick, when Allison was running a lab at the University of California, Berkeley.
June is Cancer Immunotherapy Month [CANCER RESEARCH Catalyst] In recognition of June as Cancer Immunotherapy Month, organized by our colleagues at the Cancer Research Institute (CRI), the AACR has compiled the following resources.
	5.2 Pharma
Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers [Lilly] U.S. Food and Drug Administration (FDA) previously granted olaratumab with Priority Review, Fast Track, Orphan Drug and Breakthrough Therapy designations. European Medicines Agency (EMA) is currently reviewing olaratumab under an accelerated assessment schedule.
	5.2.1 Pharma - Partenariats
Pierre Fabre, Merck KGaA team up for MEK-BRAF-Erbitux cancer combo trial [FierceBiotech] The Phase III trial will test the BRAF and MEK inhibitors Pierre Fabre licensed from Array last year in combination with Merck KGaA’s Erbitux.
	5.2.3 Pharma - économie
Pfizer just raised drug prices by an average of nearly 9 percent [STAT] This marks the second time this year that the drug maker has substantially boosted prices for its prescription drugs. Back on Jan. 1, pfizer raised prices by an average of 10.4 percent.
	5.3 Traitements - FDA, EMA,...
Researchers Propose Framework to Validate Surrogate Endpoints [RAPS] A team of researchers and health officials, including European Medicines Agency (EMA) Executive Director Guido Rasi, are proposing a three-step validation process to enhance the use of surrogate endpoints in regulatory and reimbursement decision-making.
Single, central platform now mandatory for all periodic safety update reports [EMA] As of 13 June 2016, all periodic safety update reports (PSURs) for human medicines authorised in the European Union (EU) must be submitted to the PSUR repositoryExternal link icon, which has been developed by the European Medicines Agency (EMA) in close collaboration with EU Member States and the industry.
	5.5.1 ASCO (général)
Notes from ASCO 2016 [Open Reading Frame] In contrast to the disappointing data with ADCs, this year’s ASCO included impressive data sets for two naked antibodies: Darzalex and IMAB362.
	5.5.8 ASCO (poumon)
Lung Cancer Highlights from ASCO [Lung Cancer Alliance] Some of the most exciting news came from possible new treatment options on the horizon for small cell lung cancer (SCLC)! No major treatment advances have been seen in SCLC for the past 30 years, but we are hopeful that this will soon change.
The Surprising Degree By Which MoovCare, A Web App, Helps Cancer Patients Live Longer [Forbes] While listening to Dr. Denis’s presentation, I wondered: How can an app make such a difference? It seems dreamy, but there’s nothing magical about the app. Perhaps the algorithm is better than a physician’s judgment, for prompting an exam or change in care.
	5.9.3 EHA
New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial [BMS] Among patients who responded to Opdivo, estimated median duration of remission was 7.8 months.
Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association [BMS] “The research being presented at EHA demonstrates our commitment to hematologic malignancies with high unmet need, including multiple myeloma, classical Hodgkin lymphoma and chronic myeloid leukemia.”
BLINCYTO Blinatumomab Improved Overall Survival In Patients With BCell Precursor Acute Lymphoblastic Leukemia [Amgen] Results Presented at EHA Presidential Symposium and Recognized as Top Abstract.
Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab [EHA] The registrational trial, Checkmate 205, is a Phase 2 evaluating Nivolumab with classical Hodgkin lymphoma (cHL). Reported here are the results from one cohort: patients with cHL after failure of both ASCT and subsequent brentuximab vedotin treatment.
Stopping Tyrosine Kinase Inhibitors in a Very Large Cohort of European Chronic Myeloid Leukemia Patients: Results of the EURO-SKI Trial [EHA] 868 patients at 61 sites in 11 European countries were registered in study.
Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients [EHA] linatumomab is the first immunotherapy agent that has proven to extend patients life with relapsed acute lymphoblastic leukemia when compared to chemotherapy.
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence [EHA] Persisting mutations were more frequent in older patients. Importantly, patients with persisting mutations had a higher risk of subsequent disease recurrence compared to those with no persisting mutation.
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study [EHA] At the pre-planned interim analysis, an unprecedented 63% reduction in the risk of progression or death was shown in the daratumumab group compared with control group, leading to early unblinding of the study.
	6.1 Observation
Prescription habits predict compliance with breast cancer pills [Reuters] "Whatever trait it is in you, whatever your personal quirk is that makes you obsessive compulsive or sloppy about your pill taking, that holds true for your chronic disease pills or oncology pills," Neugut said.
	6.10 Politiques
Stanford Medicine X Leads Precision Medicine Workshop At The White House [Scope Blog] Chu was invited by the White House to co-create and co-host this unique event in recognition of Medicine X’s leadership in precision medicine and engaging patients as partners in academic medicine.
Colombia plans to unilaterally lower the cost of a Novartis cancer drug [STAT] Gaviria stopped short of pursuing a compulsory license, which would have allowed the government to sidestep the Novartis patent for the drug so that generic companies could make lower-cost versions. Such a move is permitted under World Trade Organization rules.
Colombia to set new price for Novartis cancer drug: minister [Reuters] Novartis will be legally obliged to sell the drug, used to treat leukemia and other cancers, at the new price.
	6.7 DMP, Big Data & applis
Using big data, scientists discover biomarkers that could help give cancer patients better survival estimates [UCLA] The technique is an innovative way of using biomedical big data — which gleans patterns and trends from massive amounts of patient information — to achieve precision medicine — giving doctors the ability to better tailor their care for each individual patient.